Inhibikase therapeutics inc
Webb4 apr. 2024 · Inhibikase Therapeutics has an analyst consensus of Hold. The company has a one-year high of $1.44 and a one-year low of $0.44. Currently, Inhibikase Therapeutics has an average volume of 441K ... Webb16 mars 2024 · Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.
Inhibikase therapeutics inc
Did you know?
Webb9 apr. 2024 · 2w. Inhibikase will report financial results for the fourth quarter and full-year ended December 31, 2024 on Friday, March 31, 2024, after the close of U.S. markets. Following the announcement ... Webb3 apr. 2024 · Inhibikase Therapeutics, Inc. News Summary IKT US45719W1062 INHIBIKASE THERAPEUTICS, INC. (IKT) Add to my list Report Summary Quotes …
Webb2024年1月25日，临床阶段制药公司Inhibikase Therapeutics, Inc.宣布发表研究报告，描述IkT-148009作为帕金森病和相关疾病新疗法的潜力。研究结果表明，IkT-148009有能力阻止疾病的发展，推动功能恢复，并保护大脑中的神经元不被影响。数据证明了IkT-14809作为一种疾病调节疗法的潜力，并支持IkT-148009继续进行 ... Webb10 apr. 2024 · Company Profile IKT. Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline ...
WebbInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is … Webb31 mars 2024 · Inhibikase's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c …
Webb10 apr. 2024 · Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. It operates through RAMP™ Drug...
WebbInhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic … inductive tankWebb23 mars 2024 · BOSTON and ATLANTA , March 23, 2024 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the … logbook hsn codeWebbInhibikase Therapeutics Inc Modag GmbH Neuropore Therapies Inc Newron Pharmaceuticals SpA ProMIS Neurosciences Inc Stealth BioTherapeutics Corp United Neuroscience Ltd Voyager Therapeutics Inc PURCHASE OPTIONS $1,799 $1,999 log book holder wall mountedWebbTranslations in context of "Therapeutica" in French-English from Reverso Context: Oreiller de voyage Therapeutica petit (109-363) inductive tachometer near meWebb21 apr. 2024 · The latest Tweets from Inhibikase Therapeutics (@inhibikase). Inhibikase (Nasdaq: $IKT) is developing disease … inductive tachometer sensorWebb29 mars 2024 · Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial … inductive tasksWebb9 apr. 2024 · According to the Parkinson's Foundation Parkinson's Prevalence Project an estimated 1.2 million people in the U.S. will be living with Parkinson's … logbook hugo theme